Navigation Links
EpiVax Launches Precision Cancer Immunotherapy Venture, EpiVax Oncology
Date:9/25/2017

PROVIDENCE, R.I., Sept. 25, 2017 /PRNewswire/ -- EpiVax, Inc., a leader in the fields of immunogenicity assessment, vaccine design, and immune-engineering today announced the launch of EpiVax Oncology Inc., a company focused on the development of personalized therapeutic cancer vaccines. EpiVax has provided $500,000 in seed funding and has provided exclusive access to enabling technologies to the new precision immunotherapy venture. Gad Berdugo MSc Eng., MBA will lead EpiVax Oncology as Chief Executive Officer. Gad brings over 25 years of biotechnology operational, strategic partnering and financial experience gained at Abbott, Baxter, and Lazard, as well as emerging cancer biotechnology companies.

EpiVax Oncology's approach to precision immunotherapy is based on mutated, tumor-specific epitopes, termed Neo-Epitopes, which generate highly potent specific T cell responses against a wide range of tumor types. The company uses genetic profiling (via NGS sequencing) to generate therapeutic vaccines customized for each cancer patient's unique tumor load. EpiVax Oncology vaccines can be used in combination with checkpoint inhibitors or potentially as single agents.

EpiVax Oncology's key competitive advantage is centered on a streamlined, validated, commercial-grade Neo-Epitope in silico discovery platform called Ancer™. The Ancer™ platform is powered by EpiVax's EpiMatrix™ and JanusMatrix™ predictive algorithms and exclusively licensed to EpiVax Oncology for the field of cancer. Ancer™ identifies highly immunogenic, Class I and Class II, CD4 and CD8, T cell Neo-Epitopes while selecting out Treg-like epitopes. Candidate Neo-epitopes are qualified and ranked using a proprietary process designed to strengthen vaccine efficacy and decrease the incidence of immune-related adverse events. In head-to-head comparisons, Ancer™ is significantly better at Neo-Epitope identification than public or academic platforms.

"Ancer™ is setting EpiVax Oncology apart from emerging companies such as Neon Therapeutics, Gritstone Oncology and BioNtech. EpiVax Oncology will leverage EpiVax's world class excellence in computational immunology, genomics and vaccine design, built over the last 20 years, to create safe, effective, and affordable immunotherapies. We are committed to delivering on the promise of precision medicine," said Gad Berdugo.

CLINICAL DEVELOPMENT: EpiVax Oncology is initially preparing for Phase 1b clinical trials in bladder cancer and melanoma using Ancer™-derived Neo-Epitopes formulated in a proprietary clinically-tested delivery vehicle. The first trials are planned to start in 2018.

CAPITAL RAISE: EpiVax Oncology is a fully independent company currently conducting a $2M bridge capital raise to prepare for an IND as well as a $10M to $25M Series A financing to fund the first-in-man clinical trials.

ABOUT EPIVAX: EpiVax, Inc. is a privately-held biotechnology company focused on the development of vaccines and immunotherapies mainly for infectious diseases and autoimmunity. Led by Annie S. De Groot, M.D., an internationally recognized vaccine design thought leader, and William Martin, chief architect of the EpiMatrix Epitope Discovery Platform, EpiVax has enjoyed significant success in the fields of immunology and bioinformatics.

http://www.EpiVax.com
http://www.EpiVaxOnco.com

Media Contacts:
Gad Berdugo
EpiVax Oncology
gberdugo@epivaxonco.com
+1 (646) 912-2525

Anne S. De Groot MD
EpiVax
AnnieD@EpiVax.com
+1 (401) 952-4227

View original content with multimedia:http://www.prnewswire.com/news-releases/epivax-launches-precision-cancer-immunotherapy-venture-epivax-oncology-300525002.html


'/>"/>
SOURCE EpiVax, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. EpiVax Reports $5.2 Million for New Q Fever Vaccine Means There is Hope for Vaccines On Demand
2. EpiVax: Investition von 5,2 Millionen $ in neuen Impfstoff für Q-Fieber bedeutet Hoffnung für Impfstoffe auf Abruf
3. $5.8 Million Awarded For Vaccine Engineering Will Use "Immune History" To Protect Against Bird Flu, A Collaboration Led By EpiVax
4. X-Change Corporation Launches Upgraded Version of Phytiva Website, As Company Targets Distribution of Phytiva Product Line in United States and Worldwide, Extracts and New Products in Europe
5. PENTAX Medical Launches Industrys Highest* Resolution HD+ Imaging Technology For Flexible Endoscopy
6. Sequent Medical, Inc. Launches New SL Family of WEB Aneurysm Embolization Devices
7. Research-based Pharmaceutical Industry Launches Do You Mind? Campaign to Fight Mental and Neurological Disorders
8. WomanCare Global launches Simplant, Long-acting Reversible Contraception, in Chile
9. Scientific and Technical Evaluation of Pharmaceuticals, Inc. [STEPh, Inc.], Launches New Competitive Intelligence Web Site
10. Z-Medica Launches New Line of Hemostatic Agents for use in Emergency Medical Services
11. TMA Launches Physician Services Organization for Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2018)... ... 14, 2018 , ... Reiter Affiliated Companies (RAC) ... educational program developed for students throughout California. , More than fifty ... spent a minimum of 6 weeks of their summer with RAC receiving on-the-job ...
(Date:8/11/2018)... (PRWEB) , ... August 11, 2018 , ... ... a new episode of ‘Information Matrix’ on integrative medicine. The episode will go ... people in the society. , Integrative medicine involves using both conventional and complementary ...
(Date:8/7/2018)... ... August 06, 2018 , ... Drs. Jonathan and Kenneth ... using laser dentistry techniques. Using their BIOLASE WaterLase® dental laser, this modern practice, ... Perio™. , Affecting the lives of millions of Americans, gum disease can appear ...
Breaking Medicine Technology:
(Date:8/15/2018)... ... August 15, 2018 , ... Many people might desire more ... achieve it. That’s where a great new option comes in: Injectable filler, which can ... Au, MD of Advanced Dermatology P.C. , An increasingly popular option for ...
(Date:8/15/2018)... ... 15, 2018 , ... Trumpet Behavioral Health (“Trumpet”) is pleased ... Behavior Analysis in Practice, one of the leading journals in the field of ... officer for Trumpet, leading the company’s research clinical standards and training initiatives. , ...
(Date:8/14/2018)... , ... August 14, 2018 , ... ... groups, today announced new leadership roles for healthcare executives Simon Frisch and Chris ... President, Florida, respectively. They assume their roles at a time of tremendous growth ...
(Date:8/14/2018)... ... August 14, 2018 , ... Eagle Merchant Partners and ... provider of residential and commercial recreational surfacing products across the country. , The ... used across a wide range of markets and customers. Founded in 1998, Recreational ...
(Date:8/11/2018)... ... August 10, 2018 , ... TopConsumerReviews.com ... Relief. , What is gout? This painful, persistent condition originates in the liver ... high levels of uric acid. Other contributing factors may be medication side effects, ...
Breaking Medicine News(10 mins):